SELECTA BIOSCIENCES (SELB) Covered Calls

You can sell covered calls on SELECTA BIOSCIENCES to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for SELB (prices last updated Wed 12:50 PM ET):

SELECTA BIOSCIENCES (SELB) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
14.14 +0.09 14.11 14.19 41K - 0.3B
Covered Calls For SELECTA BIOSCIENCES (SELB)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Sep 21 15 0.00 14.19 0.0% 0.0%
Oct 19 15 0.00 14.19 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis. It is also developing SEL-403 product candidate, a combination therapy comprising SVP-rapamycin and LMB-100, which is in Phase I clinical trial for the treatment of patients with malignant pleural or peritoneal mesothelioma; and SELA-070, a nicotine vaccine product candidate that is in Phase I clinical trial for smoking cessation and relapse prevention. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a lead gene therapy program for the treatment methylmalonic academia; and SEL-313, a gene therapy product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., BIND Therapeutics, Inc., and Massachusetts Eye and Ear Infirmary, as well as research collaboration agreements with National Cancer Institute. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.